Shockwave Medical Inc expected to post earnings of 98 cents a share - Earnings Preview

Shockwave Medical

04/05/2024 03:06

* Shockwave Medical Inc  SWAV.OQ   SWAV.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 6 for
the period ending March 31 2024
    * The Santa Clara California-based  company is expected to
report
a 28.9% increase in revenue to $207.69 million from $161.07
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Shockwave Medical Inc is
for
earnings of 98 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Shockwave
Medical
Inc is $335.00​, above​ its last closing price of $330.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.89        0.89       1.16      Beat    30.5
 Sep. 30 2023  0.80        0.79       0.92      Beat    15.9
 Jun. 30 2023  0.88        0.86       0.76      Missed  -11.1​
 Mar. 31 2023  0.81        0.81       1.03      Beat    27.3
 ​​Dec.        1.01        1.01       1.18      Beat    17.4
 31 2022                                                
 Sep. 30 2022  0.67        0.67       0.92      Beat    37.6​
 Jun. 30 2022  0.44        0.44       0.68      Beat    54.5
 Mar. 31 2022  0.18        0.18       0.39      Beat    111.6
 This summary was machine generated May 4 at 02:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)